Aldesleukin Articles
Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal
27 January 2010
Chiron to discontinue tezacitabine program
29 March 2004
Israeli Rx import safety fears: funds and hospitals must take responsibility, says MoH
23 February 2004
Change in US policy adds cancer option, says Chiron
6 October 2003
Chiron Corp 2001 revenues top $1 bill
11 February 2002
Solid set of results for Chiron in 2000
1 February 2001
Chiron third-quarter profits jump
1 November 2000
Chiron Corp to acquire PathoGenesis for $700 million in cash
15 August 2000
Chiron second-quarter profits soar 70%
7 August 2000
Chiron's Proleukin shows promise in HIV
10 July 2000
Proleukin label change shows long-term effect
10 July 2000
Chiron pleases analysts, cutting jobs
3 November 1999
FDA OKs expanded indications for B-MS' Zerit and Videx
10 September 1999
Stock Commentary New York
19 August 1999
Chiron files additional Proleukin survival data
19 August 1999
Maxim And BioNative's RCC Collaboration
21 September 1998
Many US Companies Go Into The Black For 2nd Qtr
5 August 1998
IL-2 Boosts Immunity In Advanced HIV
26 June 1998
Maxim Progresses With Maxamine Trials
26 February 1998
Proleukin Approved For Melanoma In USA
15 January 1998
Submissions Filed In Canada For Proleukin And Photofrin
7 August 1997
Chiron's IL-2 In Melanoma
30 May 1997
US Quarterly Financial Results Round-Up
5 May 1997
Chiron Submits BLA For Proleukin
21 April 1997
US Biopharma Firms See Research Bear Fruit In '96
17 February 1997
Interleukin-2 Boosts CD4 Cells In HIV
5 August 1996
US Govt Starts CenTNF Plus IL-2 Study In HIV-1
2 October 1995
Results US Biopharmaceutical Firms Progress In Second Quarter
4 September 1995
IL-2 Shows Promise In HIV Therapy...
13 March 1995
Chiron Approval
20 February 1995
Chiron Shares Soar On Ciba Stake Rumors
21 November 1994
Improving IL-2 Therapy With MAbs
22 August 1994
REVENUES COME IN FROM BETASERON AT CHIRON
14 March 1994
ONCOTHERAPEUTICS UNVEILS NEW TRIALS
7 March 1994
US BIOTECH FIRMS POST GOOD 1st QTRs
17 May 1993
IL2 UNCERTAIN IN RENAL CELL CARCINOMA?
3 May 1993
US BIOTECHNOLOGY COS REPORT 1992 RESULTS
15 March 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
CHIRON'S IL-2 APPROVED IN USA
11 May 1992
EUROCETUS TO MARKET PROLEUKIN
27 April 1992
IL-2 APPROVED IN UK
9 March 1992
US HOSPITALS FEAR DISCOUNT "DISASTER"
10 February 1992
US RECOMMENDATION FOR PROLEUKIN
27 January 1992
FAVORABLE FORECASTS FOR US BIOTECH
13 January 1992
Showing 1-46 of 46 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
